W
Weidong Yang
Researcher at University of Maryland, Baltimore
Publications - 11
Citations - 3434
Weidong Yang is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Multiple drug resistance & Abcg2. The author has an hindex of 10, co-authored 11 publications receiving 3235 citations. Previous affiliations of Weidong Yang include University of Maryland Marlene and Stewart Greenebaum Cancer Center.
Papers
More filters
Journal ArticleDOI
A multidrug resistance transporter from human MCF-7 breast cancer cells
L. Austin Doyle,Weidong Yang,Lynne V. Abruzzo,Tammy Krogmann,Y. Gao,Arun K. Rishi,Douglas D. Ross,Douglas D. Ross +7 more
TL;DR: In this article, the authors identify a 2.4-kb mRNA that encodes a 663-aa member of the ATP-binding cassette superfamily of transporters that they termed breast cancer resistance protein (BCRP).
Journal Article
Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein.
TL;DR: It is reported that FTC almost completely reverses resistance mediated by BCRP in vitro and is a pharmacological probe for the expression and molecular action of this transporter.
Journal ArticleDOI
Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.
Douglas D. Ross,Weidong Yang,Lynne V. Abruzzo,William S. Dalton,Erasmus Schneider,Hermann Lage,Manfred Dietel,Lee Greenberger,Susan P.C. Cole,L. Austin Doyle +9 more
TL;DR: In this article, the prevalence of BCRP overexpression in cell lines selected for growth in the presence of mitoxantrone was found to be a major cellular defense mechanism elicited in response to exposure to this drug.
A multidrug resistance transporter from human MCF-7 breast cancer cells (erratum in PNAS USA 1999; 96(5): 2569)
TL;DR: Enforced expression of the full-length BCRP cDNA in MCF-7 breast cancer cells confers resistance to mitoxantrone, doxorubicin, and daunorubicsin, which causes an ATP-dependent enhancement of the efflux of rhodamine 123 in the cloned transfected cells.
Journal Article
Timed Sequential Therapy of Acute Leukemia with Flavopiridol: In Vitro Model for a Phase I Clinical Trial
Judith E. Karp,Douglas D. Ross,Douglas D. Ross,Weidong Yang,Michael L. Tidwell,Yuetong Wei,Jacqueline Greer,Dean L. Mann,Takeo Nakanishi,John J. Wright,A. Dmitri Colevas +10 more
TL;DR: These findings support a clinical trial of timed sequential therapy where flavopiridol is given for cytoreduction and subsequent priming of remaining leukemic cells for enhanced cycle-dependent drug cytotoxicity.